A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity

被引:2
作者
Chen, Jie [1 ]
Yue, Jiang [1 ]
Fu, Jingjing [1 ]
He, Shengyun [2 ]
Liu, Qianjing [1 ]
Yang, Minglan [1 ]
Zhang, Wang [1 ]
Xu, Hua [1 ]
Lu, Qing [2 ,4 ]
Ma, Jing [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, Shanghai 200127, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Endocrinol & Metab, 160 Pujian Rd, Shanghai 200127, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiol, 160 Pujian Rd, Shanghai 200127, Peoples R China
关键词
Non-alcoholic fatty liver disease (NAFLD); Magnetic resonance imaging proton density fat fraction (MRI-PDFF); Obese; Overweight; HEPATIC STEATOSIS; DIAGNOSIS; PREVALENCE; BIOPSY;
D O I
10.1507/endocrj.EJ23-0227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The global prevalence of non-alcoholic fatty liver disease (NAFLD) has attained a level of 25.24%. The prevalence of NAFLD in China has exhibited an upward trajectory in parallel with the increasing incidence of obesity over the preceding decade. In order to comprehensively assess hepatic lipid deposition in individuals with overweight or obesity, we have devised a pioneering prognostic formula that capitalizes on clinical parameters. To this end, we have conducted a cross-sectional cohort study involving 149 overweight or obese subjects. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) has been employed to evaluate the extent of liver fat accumulation. Through univariate analysis, we have identified potential factors, and the definitive elements in the prediction model were selected utilizing the forward stepwise regression algorithm. The Shang Hai Steatosis Index (SHSI) incorporates alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting insulin, and 1-h postload glycaemic levels, thereby furnishing the capability to predict NAFLD with an area under the receiver operator characteristic (AUROC) of 0.87. By establishing a threshold value of 10.96, determined through Youden's index, we have achieved a sensitivity of 69.57% and a specificity of 88.24%. The Spearman correlation coefficient between liver fat fraction ascertained by MRI-PDFF and that predicted by the SHSI equation amounts to 0.74. Consequently, the SHSI equation affords a dependable means of predicting the presence of NAFLD and liver fat accumulation within the overweight and obese population.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
[31]   Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) [J].
Cuthbertson, Daniel J. ;
Koskinen, Juha ;
Brown, Emily ;
Magnussen, Costan G. ;
Hutri-Kahonen, Nina ;
Sabin, Matthew ;
Tossavainen, Paivi ;
Jokinen, Eero ;
Laitinen, Tomi ;
Viikari, Jorma ;
Raitakari, Olli T. ;
Juonala, Markus .
ANNALS OF MEDICINE, 2021, 53 (01) :1256-1264
[32]   Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes [J].
Shao, Ning ;
Kuang, Hong Yu ;
Hao, Ming ;
Gao, Xin Yuan ;
Lin, Wen Jian ;
Zou, Wei .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (06) :521-529
[33]   Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD) [J].
Kragh Petersen, Sine ;
Bilkei-Gorzo, Orsolya ;
Govaere, Olivier ;
Hartlova, Anetta .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (05)
[34]   Effect of berberine on a cellular model of non-alcoholic fatty liver disease [J].
Liu, Yanni ;
Zhang, Zhixin .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (12) :16360-16366
[35]   Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis [J].
Sharma, Praveen ;
Arora, Anil .
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5
[36]   Non-alcoholic fatty liver disease (NAFLD) models in drug discovery [J].
Cole, Banumathi K. ;
Feaver, Ryan E. ;
Wamhoff, Brian R. ;
Dash, Ajit .
EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (02) :193-205
[37]   In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD) [J].
Kanuri, Giridhar ;
Bergheim, Ina .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06) :11963-11980
[38]   Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD) [J].
Parameswaran, Madhangi ;
Hasan, Hamzah A. ;
Sadeque, Jafor ;
Jhaveri, Sharan ;
Avanthika, Chaithanya ;
Arisoyin, Abimbola E. ;
Dhanani, Maulik B. ;
Rath, Swaroopa M. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
[39]   Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts [J].
Papatheodoridi, Margarita ;
Cholongitas, Evangelos .
CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) :4574-4586
[40]   The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience [J].
Boulouta, Anna ;
Aggeletopoulou, Ioanna ;
Kanaloupitis, Stavros ;
Tsounis, Efthymios P. ;
Issaris, Vasileios ;
Papantoniou, Konstantinos ;
Apostolos, Anastasios ;
Tsaplaris, Paraskevas ;
Pastras, Ploutarchos ;
Sotiropoulos, Christos ;
Tsintoni, Aggeliki ;
Diamantopoulou, Georgia ;
Thomopoulos, Konstantinos ;
Michalaki, Marina ;
Triantos, Christos .
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (05)